ATOS Stock Analysis: Buy, Sell, or Hold?
ATOS - Atossa Therapeutics, Inc. Common Stock
$1.77
0.02 (1.14%)
▲
5d:
-10.83%
30d:
-64.24%
90d:
-67.34%
WAIT
LOW Confidence
Analysis Updated: Jun 25, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When ATOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ATOS is down 10.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ATOS is down 10.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ATOS is currently trading at $1.77, which is considered oversold relative to its 30-day fair value range of $2.46 to $5.17.
Technical Outlook: Technically, ATOS is in a downtrend. Immediate support is located at $1.70, while resistance sits at $2.81.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $22.00 (+1142.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATOS is in a downtrend. Immediate support is located at $1.70, while resistance sits at $2.81.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $22.00 (+1142.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.46 -
$5.17
Company Quality Score
44/100
(HOLD)
Options IV Signal
49th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 49th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1142.9% below Wall St target ($22.00)
- WARNING: Recommendation downgraded due to -10.8% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.46 -
$5.17
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.39
(21.9%)
Support & Resistance Levels
Support Level
$1.70
Resistance Level
$2.81
Current Trend
Downtrend
Technical data as of
Jun 25, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.40
Wall Street Target
$22.00
(+1142.9%)
Share & Embed Analysis
Last updated: June 26, 2026 12:52 AM ET
Data refreshes hourly during market hours. Next update: 1:52 AM
Data refreshes hourly during market hours. Next update: 1:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 63 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 60 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 65 BUY |
